AI Cuts Antibody Discovery Time to Under 5 Weeks

Creating new antibody treatments just got dramatically faster, thanks to artificial intelligence that can design and validate potential medicines in under five weeks.

Converge Bio has developed an integrated workflow that combines AI-guided design with automated laboratory testing. The system eliminates months of traditional trial and error by predicting which antibody designs will work best before scientists even start building them in the lab.

The breakthrough solves a longstanding problem in drug development. While AI has shown promise in designing antibodies on computers, translating those digital predictions into real, working molecules has remained slow and difficult. This new approach bridges that gap by automating the entire process from design through testing.

CEO Dov Gertz will present case studies from multiple therapeutic targets in an upcoming webinar hosted by Converge Bio and Twist Bioscience. The presentation will showcase how the system has successfully accelerated antibody discovery across different disease areas while maintaining the rigorous testing needed for medical applications.

The system works by using AI to generate antibody designs, then automatically building and characterizing those molecules using high-throughput laboratory equipment. This design-build-test cycle runs continuously, with each round of results feeding back into the AI to improve future predictions.

The Ripple Effect

Faster antibody development means patients with serious diseases could access new treatments years sooner than current timelines allow. Antibodies represent some of the most important medicines available today, treating everything from cancer to autoimmune diseases to infectious conditions.

The technology also makes antibody development more accessible. Smaller biotech companies and academic researchers who previously lacked resources for lengthy development cycles can now compete in creating life-saving treatments. More researchers working on antibody medicines means more potential cures reaching more patients.

The webinar will also address current limitations of generative AI in antibody engineering, providing transparency about what the technology can and cannot yet accomplish. This honest assessment helps set realistic expectations while celebrating genuine progress.

The integration of AI with automated laboratory systems represents a new chapter in drug discovery. As these technologies continue improving, the timeline from identifying a disease target to testing a potential treatment in patients will keep shrinking, bringing hope faster to those who need it most.